Is Retatrutide Approved in Other Countries? Global Status (2026)

The Short Answer: Retatrutide Is Not Approved Anywhere in the World

Retatrutide is investigational on a global basis as of June 2026. The five regulatory bodies that matter most to English-speaking searchers have all taken the same position by default, because none of them has anything to review yet: the FDA (United States), the EMA (European Union), the MHRA (United Kingdom), the TGA (Australia), and Health Canada. A drug only becomes "approved" after a company submits a formal application and the agency completes its review. Eli Lilly has not submitted retatrutide to any of these agencies, so there is no approval to point to. For the United States specifics, our retatrutide FDA approval status page goes deeper.

What "Investigational" Means vs. "Approved"

An investigational drug is one that is still undergoing clinical trials. It has no regulatory clearance and cannot be prescribed commercially in any country. An approved drug has cleared a full Phase 3 review by a regulator, can be prescribed by licensed physicians, and is typically eligible for insurance coverage. That distinction is the conceptual anchor for every jurisdiction below: until at least one agency grants a marketing authorization, retatrutide stays investigational everywhere.

Regulatory Agency Overview: Who Approves Drugs in Each Country

Each major market has its own regulator with its own process, but the structure is similar everywhere. A drugmaker files an application, the agency reviews the trial data, and only then does the drug become legally prescribable. The table below shows where retatrutide stands with each of the five agencies and the projected approval windows, which are analyst estimates rather than confirmed dates.

Projected approval windows are analyst estimates based on TRIUMPH trial completion timelines and standard review periods. Eli Lilly has not publicly confirmed submission or approval dates.

United States (FDA)

FDA Status as of June 2026

Retatrutide is not approved by the FDA. No application has been filed yet: Phase 3 TRIUMPH results have been reported, and Lilly plans to submit a Biologics License Application (BLA) in Q1 2027. Eli Lilly's own consumer FAQ confirms the point directly: retatrutide is not FDA approved. For the full United States picture, see our retatrutide FDA approval status guide and the detailed retatrutide FDA submission timeline.

What Comes Before FDA Approval

The sequence is fixed. Phase 3 TRIUMPH results have been reported, and Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027, after completing its chemistry, manufacturing and controls package. The FDA's standard review typically takes about a year and runs faster under priority review, so approval could come in the 2027 to 2028 window if the timeline holds. The approval date is not confirmed by Lilly.

European Union (EMA)

EMA Status as of June 2026

Retatrutide is not approved in the European Union. The European Medicines Agency does not begin a review until a company submits a Marketing Authorization Application, and Lilly has not submitted one. Phase 3 TRIUMPH trials are active in EU countries including Germany, France, and Spain, but that access is limited to enrolled trial participants.

How Long Does EMA Review Take After FDA?

For major obesity drugs, EMA approval has typically followed FDA approval by about 12 to 18 months. On that basis, EU commercial availability is projected for 2028 to 2029. The lag exists because the EMA has its own evidence requirements, including EU-specific safety data, and the European Commission must grant the final marketing authorization after the EMA issues a positive opinion.

Country-Level Variation Within the EU

Even after EMA approval, individual member states control pricing and reimbursement on their own schedules. France, Germany, and the Netherlands tend to offer faster national access than many southern and eastern European countries, so "available in the EU" does not mean available everywhere on the same day.

United Kingdom (MHRA and NICE)

MHRA Status as of June 2026

Retatrutide is not approved in the United Kingdom. The Medicines and Healthcare products Regulatory Agency has received no submission from Lilly, and the drug is not licensed for any indication in the UK.

MHRA Timeline After FDA Approval

The MHRA has typically followed FDA approval within 6 to 12 months for major obesity drugs. The precedent often cited is tirzepatide: Mounjaro received FDA approval for type 2 diabetes in May 2022 and MHRA marketing authorization in September 2022, per the MHRA Products register [MHRA]. If the FDA approves retatrutide in 2027, UK approval could follow in late 2027 or early 2028. For how this compares with an already-approved drug, see tirzepatide's FDA approval pathway.

NICE Approval for NHS Prescribing

There is a second UK step that catches many people out. Even after MHRA licensing, the National Institute for Health and Care Excellence must complete a health technology assessment before the NHS will fund prescriptions. That adds roughly 6 to 18 months after MHRA approval. The precedent again is Mounjaro, MHRA-approved in September 2022 but not recommended by NICE for NHS use in type 2 diabetes until its March 2023 technology appraisal, NICE TA924 [NICE TA924].

Australia (TGA)

TGA Status as of June 2026

Retatrutide is not approved in Australia. The Therapeutic Goods Administration has received no submission from Lilly. Phase 3 TRIUMPH trial sites have operated in major Australian cities, but most retatrutide Phase 3 trials are no longer enrolling, and only enrolled participants have investigational access.

TGA and PBS Timeline

The TGA has typically approved medications 6 to 18 months after FDA approval, which puts projected Australian commercial availability around 2028. After TGA approval there is a further step: the Pharmaceutical Benefits Scheme must approve subsidized access, which can add another 12 to 24 months. The precedent here is semaglutide, with Ozempic entered on the TGA Australian Register of Therapeutic Goods in 2019 [TGA ARTG] and PBS-listed for type 2 diabetes in 2020 [PBS].

Canada (Health Canada)

Health Canada Status as of June 2026

Retatrutide is not approved in Canada. Health Canada has not received a New Drug Submission from Lilly. Phase 3 TRIUMPH trials have run at Canadian sites in provinces including Ontario, Quebec, and British Columbia, with investigational access restricted to trial participants.

Health Canada Timeline

Health Canada often reviews in parallel with the FDA and can approve a drug 6 to 12 months after US approval. On that basis, Canadian commercial availability is projected for late 2027 or 2028, contingent on the FDA approving on schedule first.

Why Retatrutide Is Not Yet Approved in Other Countries

Drug Approval Is Sequential

You cannot skip steps. Retatrutide must finish Phase 3, then Lilly files its application with each agency, then each agency reviews, and only then can approval happen. The TRIUMPH program is the prerequisite for all of it. Until Lilly files, no regulator has the authority to review the drug, which is why every jurisdiction reads the same: investigational.

The TRIUMPH Program Is Still Running

The TRIUMPH clinical development program spans 13 countries and has enrolled over 5,800 participants. It is the data package Lilly needs before it can file with any agency. For the trial details and how to enroll, see our TRIUMPH Phase 3 clinical trials guide. This article stays in regulatory framing and does not cover trial outcome figures.

"Research Peptide" Sales Are Not Approval

Some people see retatrutide sold online and assume it must be approved somewhere. It is not. Research peptide retatrutide is sold labeled for laboratory use only. It is not FDA, EMA, or MHRA cleared for human use in any form, and regulators have warned that these unverified products can be hazardous. Seeing a product for sale is not the same as a country approving it.

What You Can Do Right Now While Waiting for Approval

Option 1: Enroll in a TRIUMPH Clinical Trial

For most people, the only legal way to access retatrutide today is through a clinical trial. Participation is free, the product is pharmaceutical grade, and you are medically supervised throughout. You can search active sites on ClinicalTrials.gov or start with our clinical trials guide.

If You Cannot Join a Trial: Lilly's Expanded Access Program

Lilly runs an expanded access program for retatrutide before FDA approval, "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial" (Reuters via KSL). Patients must be 18 or older with a BMI of 35 or more despite tolerating the highest available dose of weight-management therapy, have two or more serious or life-threatening obesity-related complications, be unable to join an ongoing retatrutide (or comparable) trial, and have discussed all standard treatment options, including bariatric surgery, with their doctor (Lilly Medical; ClinicalTrials.gov NCT07629401). The treating physician applies to the FDA as the sponsor of a patient-specific investigational new drug (IND) application and must obtain institutional review board (IRB) approval. Lilly provides the drug at no cost, and direct-to-patient shipping is not available. It is not something a patient can buy.

Option 2: Consider the Approved Alternatives

Two GLP-1 class medications are already approved in major markets. Semaglutide (Wegovy) is FDA-approved for weight management and is widely available across the EU, UK, Australia, and Canada. Tirzepatide (Zepbound) is FDA approved for weight management. Compounding is not an option: the FDA states retatrutide cannot be used in compounding under federal law. For a fuller picture of access by country, including trial options, see retatrutide availability by country. Any switch is a decision for you and your doctor.

Track the Approval Timeline

Regulatory status moves as TRIUMPH milestones are reached. The clearest place to follow the projection is our retatrutide FDA submission timeline, which we update as new data lands.

Video: a functional medicine practitioner explains the FDA approval question for retatrutide.